Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Pericarditis market is undergoing dynamic changes influenced by advancements in diagnostic techniques, evolving treatment strategies, and a deeper understanding of the underlying causes of pericardial inflammation. Pericarditis, characterized by inflammation of the pericardium, has spurred innovations in therapeutics and diagnostic tools to address the diverse spectrum of this cardiac condition.
One of the significant trends in the Pericarditis market is the integration of advanced imaging technologies for accurate diagnosis. Echocardiography, cardiac MRI, and CT scans are becoming pivotal in precisely assessing pericardial inflammation, guiding clinicians in formulating tailored treatment plans.
Biomarkers for pericarditis is of the cutting edge of clinical applications in the current market and assists in early detection and prompt response. The framed markers like C-react (CRP) and troponin help to diagnose pericarditis, tracking and monitoring the disease activity, therefore calling for a more interactive control plan.
Giving NSAIDs permits to play the role of the cornerstone in the treating pericarditis, serving as the primary approach to reduce inflammation, as well as the symptoms. Research and development dedicated to this type of regimen shows that the right balance is necessary to take into account the effectiveness of the drugs as well as the possibility of side effects that may vary among the different patient populations.
As more evidence emerges, colchicine is rapidly gaining popularity for its proprietary role in the pericarditis market, specifically in preventing relapsing pericarditis. Demonstrated in studies, colchicine is found to be a helpful combo-medication in the management of pericarditis, which lowers the probability of recurrences and ensures a better overall condition is achieved.
Investment in novel commercial solutions, such as, biologics is on the rise on the grounds of advanced stage diseases when oncologic standard treatments are futile. Biologics are new drugs targeting one or several inflammatory pathways (like the cell that produced interleukin-1 or IL-1)-innovative diagnostics for management of specific patients with chronic or recurrent (unsatisfactory response to standard) pericarditis.
Amongst the nuances of Pericarditis market, the handling of complications such as cardiac tamponade is included as well. Expansion in special physcardiocentesis techniques, hemodynamic control and percutaneous drainage is leading development on dealing with critical cases where fluid housing to the heart is accumulated.
Immunomodulators are the new shiny faces of the market, with how immune system alterations are increasingly becoming the main focus in treatment of pericarditis. Agents such as IVIG and immunosuppressants, that have been proposed for potentially mediating immune reactions in distinct pools of pericarditis patients are worthy of study at this point.
Pericarditis Market Highlights:
Global Pericarditis Market Overview
The Pericarditis Market Size was valued at USD 3.48 Billion in 2023. The Global Pericarditis industry is projected to grow from USD 3.74 Billion in 2024 to USD 6.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.56% during the forecast period (2024 - 2032).
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.
The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the pericarditis drugs market.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company with a portfolio of assets that are intended to regulate immunological pathways across a variety of diseases, announced the U.S. in March 2022.
ARCALYST ® (rilonacept) is a recombinant fusion protein that is subcutaneously injected on a weekly basis and is approved by the Food and Drug Administration (FDA) for the treatment of recurrent pericarditis and the reduction of the risk of recurrence in adults and children aged 12 years and older. This protein inhibits the signaling pathways of interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). Recurrent pericarditis is a painful autoinflammatory cardiovascular disease that primarily manifests as chest pain. It is frequently linked to changes in electrical conduction and, in some cases, the accumulation of fluid around the heart, known as pericardial effusion.
Recurrent pericarditis is diagnosed in patients who experience additional pericarditis episodes after a symptom-free period of 4-6 weeks or longer. Quality of life is impacted by recurrent pericarditis symptoms, which restrict physical activities and result in frequent emergency department visits and hospitalizations. Each year, approximately 40,000 patients in the United States seek and receive treatment for recurrent pericarditis, according to data. Out of that group, approximately 14,000 patients experience a second or subsequent event (recurrence) as a result of persistent underlying disease or an insufficient response to conventional therapies, including nonsteroidal anti-inflammatory medications (NSAIDs), colchicine, and corticosteroids.
Global Pericarditis Market Trends
The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.
Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.
The pericarditis drugs market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.
Global Pericarditis Market Segmentation
The global pericarditis market has been segmented into type, application, and end user.
Based on type, the global pericarditis drugs market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.
Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.
Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.
Global Pericarditis Market Key Players
The prominent players in the global pericarditis market are:
- Pfizer Inc.
- AstraZeneca Plc
- Novartis International AG
- Allergan plc.
- Merck & Co., Inc.
- Bayer AG
- Reckitt Benckiser Group Plc.
- PerkinElmer, Inc.
- FUJIFILM Holdings Corporation
- Sanofi
- and Johnson & Johnson Services, Inc
Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.
Global Pericarditis Market Regional Analysis
The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the global pericarditis drugs market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.
The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.
Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.
Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.
Key Updates
- In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
- In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.
- In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.
Market Segmentation
Global Pericarditis Market, by Type
- Acute Pericarditis
- Recurrent Pericarditis
- Chronic Pericarditis
Global Pericarditis Market, by Diagnosis & Treatment
- Diagnosis
- Electrocardiogram (ECG),
- Echocardiogram,
- Computerized Tomography (CT)
- X-Ray
- Treatment
- Medication
- Surgical Treatment
Global Pericarditis Market, by End User
- Hospitals & Clinics
- Medical Institutes & Research laboratories
Global Pericarditis Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Pricing Analysis
- Competitive Benchmarking for Global Pericarditis Market
Intended Audience
-
Medical device manufacturers and distributors
-
Government research organizations
-
Hospitals and clinics
-
Regulatory agencies
-
Pharmaceutical companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
